KI Intelligence™
Disease develops across multiple biological systems—but conventional diagnostics often evaluate those systems independently.
KI Intelligence™ brings molecular biomarkers, clinical factors, family history, physiological measurements, and longitudinal patient data together within a unified analytical platform. The result is a more complete view of an individual's changing risk profile and the intelligence needed to identify disease-related signals earlier.
One platform. Multiple dimensions of health. A clearer view of what may be developing.
The Data Foundation
KI Intelligence™ evaluates four distinct layers of patient information. Each layer contributes a different dimension of risk, creating a more complete understanding of the biological changes that may precede disease.
How the layers combine
Each data stream contributes distinct context. KI Intelligence™ brings them together to reveal patterns that no single input can provide on its own.
Unified patient profile
A continuously informed view of the patient becomes the foundation for contextual risk interpretation.
Disease-associated signals generated through Kihealth Labs assays and molecular-analysis programs.
Family history, inherited predisposition, lifestyle, and environmental factors that can modify the significance of an individual molecular signal.
Individual Patient Profile
A unified, longitudinal representation of molecular, clinical, physiological, and familial risk.
Patient-level variables that allow molecular findings to be interpreted within the appropriate clinical context.
Repeated measurements that distinguish an isolated result from a persistent biological trend.
Where appropriately licensed or authorized, development data may include de-identified clinical cohorts, published studies, genomic repositories, electronic health records, biobank data, and disease-specific research datasets.
Population-level evidence establishes reference patterns. Kihealth Labs’ proprietary assay and longitudinal patient data create the disease-specific intelligence layer.
The Analytical Architecture
KI Intelligence™ is not dependent on a single algorithm. It uses a disease-specific ensemble architecture in which each analytical method performs a defined function—from detecting abnormal molecular patterns to evaluating disease progression over time.
The models work together to convert complex patient data into a calibrated and clinically interpretable assessment of risk.
Quality Control
Feature Engineering
Disease-Specific Modeling
Ensemble Integration
Risk Calibration
Before modeling begins, incoming measurements are evaluated for completeness, consistency, analytical variation, and potential confounding factors.
Raw measurements are transformed into clinically meaningful analytical features that can reveal relationships not visible through isolated biomarkers.
Complementary statistical and machine-learning models evaluate different dimensions of patient risk. Select a method to view the scientific question it addresses and the result it contributes to the ensemble.
Model selection is determined by the disease, biomarker profile, available evidence, intended use, and validation requirements.
Outputs from complementary models are weighted and combined to reduce dependence on any single analytical method or individual biomarker.
The composite model output is calibrated against defined clinical outcomes and translated into a consistent, interpretable risk framework.
Proprietary Architecture
Individual modeling techniques are widely available. The proprietary advantage of KI Intelligence™ is created through the disease-specific combination of Kihealth Labs biomarkers, assay-aware normalization, engineered molecular features, longitudinal patient baselines, model weighting, outcome linkage, and risk calibration.
Proprietary Biomarkers
Assay-Aware Normalization
Disease-Specific Features
Longitudinal Baselines
Complementary Models
Clinical Outcome Linkage
Calibrated Risk Intelligence
The architecture is designed to become more differentiated as Kihealth Labs generates additional assay data, longitudinal measurements, and linked clinical outcomes.
The Proprietary Intelligence Layer
Public datasets and commonly available machine-learning methods are accessible to many organizations. The proprietary value of KI Intelligence™ is created through how Kihealth Labs generates, structures, interprets, and validates disease-specific data.
Algorithms can be replicated. A continuously expanding system of proprietary assays, longitudinal patient data, engineered features, and linked clinical outcomes is significantly more difficult to reproduce.
Six connected sources of proprietary value
KI Intelligence™ evaluates disease-specific combinations of biomarkers selected through Kihealth Labs’ discovery, translational, and clinical-development programs.
Biomarker selection · Multi-analyte signatures · Disease-specific panels
Laboratory variables—including sample quality, collection conditions, analytical platform, batch effects, and limits of detection—are incorporated into data-quality and normalization processes.
Sample integrity · Collection variability · Batch correction · Analytical limits
Raw measurements are transformed into analytical features that reveal relationships not apparent through the independent interpretation of individual biomarkers.
Biomarker ratios · Composite signatures · Interaction effects · Cross-domain relationships
Where longitudinal results are available, the patient can increasingly serve as their own biological reference—helping identify meaningful changes that may remain within broad population reference ranges.
Individual baseline · Rate of change · Direction · Persistence
Biomarker profiles become more valuable when connected to longitudinal clinical outcomes. These relationships help identify patterns associated with stability, progression, intervention, or clinical conversion.
Biomarker trajectory · Clinical outcome · Intervention response · Disease progression
Model outputs are calibrated into defined risk categories and score ranges designed to remain consistent and interpretable across patient populations and testing periods.
Risk calibration · Decision thresholds · Population performance · Clinical interpretation
The Compounding Moat
The moat is the cumulative relationship among proprietary assays, engineered features, longitudinal patient data, clinical outcomes, and disease-specific validation.
Each additional validated assay, patient measurement, and linked outcome strengthens the intelligence architecture supporting current and future Intercept programs.
How the moat compounds
Each layer below feeds the next. Proprietary assays produce engineered features, which accumulate longitudinal data, which link to clinical outcomes, which in turn receive disease-specific validation. The cycle then begins again—each pass making the whole architecture harder to replicate.
THE INTERCEPT IQ™ SCORE
The Intercept IQ™ Score translates a complex, multidimensional analysis into a standardized disease-specific risk assessment.
It is designed to communicate more than whether a result is simply “positive” or “negative.”
ILLUSTRATIVE PATIENT EXAMPLE
INTERCEPT IQ™ RISK PROFILE
Integrated molecular and clinical risk assessment
CURRENT ASSESSMENT
May 2026
INTERCEPT IQ™ SCORE
ELEVATED
Illustrative values shown for design purposes.
Risk has increased across consecutive measurements, with the greatest change occurring during the most recent testing interval.
CHANGE FROM BASELINE
+22%
RECENT RATE OF CHANGE
Increasing
High contribution
Moderate contribution
Moderate contribution
Supporting contribution
CONFIDENCE RANGE
74–82
The range reflects model uncertainty and variation within the available patient data.
Current Risk
A standardized disease-specific assessment based on the patient's current molecular and clinical profile.
Change Over Time
Comparison with prior results reveals whether measured risk is stable, increasing, or decreasing.
Why It Changed
Contributing biomarkers and clinical factors provide context for the current result.
What Happens Next
A defined monitoring or follow-up pathway connects the result with an appropriate next step.
Recommended Monitoring Pathway
REVIEW
Clinician reviews the score, contributing factors, and relevant patient history.
MONITOR
Follow-up timing is determined according to the assay's validated intended use.
REASSESS
Future results are compared with the patient's baseline and prior trajectory.
Follow-up recommendations are assay-specific and should be interpreted by a qualified healthcare professional within the appropriate clinical context.
A score should never be presented without context.
KI Intelligence™ is designed to show why risk has changed, which signals are driving the result, and how the patient's current profile compares with relevant reference populations and their own prior baseline.
From Risk Prediction to Disease Interception
Disease prevention often begins before a definitive diagnosis—but only if risk can be identified early enough to act.
KI Intelligence™ is designed to recognize the transition between background susceptibility and measurable biological change.
Family history, inherited factors, lifestyle, and existing clinical characteristics establish the patient's baseline risk.
Family history · Genetics · Lifestyle · Clinical characteristics
Disease-associated biomarkers begin to move, interact, or deviate from the patient's previous baseline.
Biomarker movement · Molecular interaction · Baseline deviation
KI Intelligence™ evaluates whether the observed changes form a meaningful and persistent disease-associated risk pattern.
Pattern persistence · Direction · Velocity · Integrated risk
The resulting intelligence may support additional testing, increased surveillance, specialist referral, or an evidence-based intervention pathway.
Additional testing · Surveillance · Referral · Intervention pathway
Subsequent testing evaluates whether the patient's measured risk trajectory is stable, increasing, decreasing, or responding following an intervention.
Stable · Increasing · Decreasing · Response monitoring
What KI Intelligence™ Evaluates
The objective is not simply to predict disease. It is to create a clinically useful window in which its trajectory may still be changed.
By identifying persistent biological change before conventional diagnostic thresholds are reached, KI Intelligence™ is designed to support more informed monitoring, evaluation, and clinically appropriate action.
This visualization is conceptual. Interception windows, risk thresholds, follow-up pathways, and clinical actions are disease- and assay-specific and must be established through appropriate validation.
A Platform Built to Expand
KI Intelligence™ provides a common analytical foundation for multiple disease-specific programs—allowing Kihealth Labs to apply the same data, modeling, validation, and risk-translation infrastructure across a growing portfolio of assays.
Disease Programs
METABOLIC
Metabolic dysfunction and diabetes-related risk.
Metabolic biomarkers · Longitudinal glycemic risk · Earlier disease visibility
NEUROLOGICAL
Neurological and neurodegenerative disease risk.
Neurological biomarkers · Disease-associated change · Longitudinal monitoring
ONCOLOGY
Cancer-associated molecular risk.
Cancer-associated signals · Molecular risk patterns · Earlier evaluation pathways
EXPANDING PIPELINE
Additional disease applications developed through the same data, modeling, validation, and risk-translation infrastructure.
New biomarkers · New disease models · New assay applications
Disease-Specific Translation
Biomarker Strategy
Disease-specific biomarker combinations and multi-analyte signatures.
Model Configuration
Analytical methods selected according to the disease, evidence, and intended use.
Clinical Validation
Performance evaluated within disease-specific populations and clinical pathways.
Risk Translation
Model outputs calibrated into interpretable scores, categories, and monitoring frameworks.
Common Analytical Foundation
A reusable intelligence architecture for integrating patient data, engineering disease-specific features, modeling risk, linking outcomes, and translating complex analysis into clinically interpretable information.
New disease programs can be developed without rebuilding the underlying analytical infrastructure.
Liquid Biopsy
Cell-free DNA, methylation marks, and circulating proteins carry a real-time read-out of tissue biology — long before symptoms and often before conventional labs shift.
Molecular Analysis
Every Intercept IQ™ result begins with rigorous wet-lab chemistry — sample stabilization, extraction, and quantification — before any computational analysis is applied.
Clinical Interpretation
Molecular intelligence is delivered as a physician-facing report grounded in biology, calibrated against validated reference ranges, and interpretable in the context of the individual patient.
Why Molecular Intelligence Matters
Molecular intelligence becomes valuable when complex biological data can be translated into information that advances patient monitoring, diagnostic development, clinical research, and therapeutic discovery.
Identify disease-associated molecular changes that may emerge before conventional clinical findings or diagnostic thresholds are reached.
Potential Value
An earlier opportunity for evaluation, monitoring, and clinically appropriate action.
Measure how biomarkers and integrated risk profiles change across multiple time points.
Potential Value
Distinguish temporary variation from persistent biological change and evaluate whether a patient's trajectory is stable, increasing, decreasing, or responding following an intervention.
Investigate relationships among molecular signals, patient characteristics, clinical information, and longitudinal outcomes.
Potential Value
Prioritize promising biomarkers, composite signatures, and disease-associated patterns for future diagnostic development.
Support research into why disease progression and therapeutic response vary among patients.
Potential Value
Inform patient stratification, identify potential responder subgroups, and explore biomarkers associated with treatment response or resistance.
Apply biomarker and risk intelligence across therapeutic-development programs.
Potential Value
Support cohort enrichment, clinical-trial recruitment, response monitoring, biomarker-defined endpoints, and companion or complementary diagnostic development.
Apply a common data, modeling, governance, and validation infrastructure across multiple disease areas.
Potential Value
Develop new disease-specific programs without rebuilding the underlying intelligence architecture for every assay.
KI Intelligence™ is designed to create value across the molecular-intelligence continuum—from identifying earlier biological change to developing new diagnostics, supporting therapeutic research, and expanding the Kihealth Labs disease-interception portfolio.
Precision Diagnostics Powered by Molecular Intelligence
The Intercept IQ™ & molecular intelligence engine combine advanced laboratory science, liquid biopsy technologies, multi-omic biomarker analysis, and computational biology to support the next generation of precision diagnostics. By translating complex molecular information into clinically meaningful insights, the platform is designed to accelerate disease interception, biomarker discovery, and precision medicine across multiple therapeutic areas.
